MX361157B - Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso. - Google Patents

Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso.

Info

Publication number
MX361157B
MX361157B MX2015002501A MX2015002501A MX361157B MX 361157 B MX361157 B MX 361157B MX 2015002501 A MX2015002501 A MX 2015002501A MX 2015002501 A MX2015002501 A MX 2015002501A MX 361157 B MX361157 B MX 361157B
Authority
MX
Mexico
Prior art keywords
inhibitor compounds
pi3k inhibitor
dioxino
oxazin
methods
Prior art date
Application number
MX2015002501A
Other languages
English (en)
Other versions
MX2015002501A (es
Inventor
Andrew Heald Robert
James Mclean Neville
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015002501A publication Critical patent/MX2015002501A/es
Publication of MX361157B publication Critical patent/MX361157B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se describen compuestos inhibidores de PI3K de dioxino- y oxazin-[2,3-d]pirimidina de la Fórmula I con actividad anti-cáncer, actividad anti-inflamatoria, o propiedades inmunoreguladoras, y más específicamente con actividad inhibidora o moduladora de PI3 cinasa. Se describen métodos para utilizar los compuestos inhibidores de PI3K tricíclicos de la Fórmula I para diagnóstico o tratamiento in vitro, in situ, e in vivo de células, organismos, o condiciones patológicas asociadas de mamíferos. (ver Fórmula).
MX2015002501A 2012-08-30 2013-08-29 Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso. MX361157B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261694898P 2012-08-30 2012-08-30
PCT/EP2013/067861 WO2014033196A1 (en) 2012-08-30 2013-08-29 Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use

Publications (2)

Publication Number Publication Date
MX2015002501A MX2015002501A (es) 2015-06-10
MX361157B true MX361157B (es) 2018-11-28

Family

ID=49080882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002501A MX361157B (es) 2012-08-30 2013-08-29 Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso.

Country Status (11)

Country Link
US (1) US9346817B2 (es)
EP (1) EP2890698B1 (es)
JP (1) JP6022691B2 (es)
KR (1) KR101697444B1 (es)
CN (1) CN104583215B (es)
BR (1) BR112015002493A8 (es)
CA (1) CA2879497C (es)
HK (1) HK1209740A1 (es)
MX (1) MX361157B (es)
RU (1) RU2612251C2 (es)
WO (1) WO2014033196A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209664B1 (en) 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
JP6473270B2 (ja) * 2015-07-27 2019-02-20 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3661919A4 (en) * 2017-08-02 2021-03-31 Northwestern University SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS AND USES THEREOF
WO2022184152A1 (zh) * 2021-03-03 2022-09-09 劲方医药科技(上海)有限公司 稠环取代的六元杂环化合物及其制法和用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
EP1409125B1 (en) 2001-07-12 2016-04-20 Reaxa Limited Microencapsulated catalyst, methods of preparation and methods of use thereof
GB0217294D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
KR20130058072A (ko) 2005-10-07 2013-06-03 엑셀리시스, 인코포레이티드 증식성 질환의 치료를 위한 ｍｅｋ 억제제로서의 아제티딘
MX2008012513A (es) 2006-04-12 2008-10-10 Basf Se 2-(piridin-2-il)-pirimidinas como fungicidas.
PT2041139E (pt) * 2006-04-26 2012-01-13 Hoffmann La Roche Compostos farmacêuticos
WO2007127183A1 (en) * 2006-04-26 2007-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
UA97483C2 (ru) * 2006-08-08 2012-02-27 Чугай Сейяку Кабушики Кайша Производное пиримидина в качестве ингибитора pi3k и его применение
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
KR101460816B1 (ko) * 2006-12-07 2014-11-12 에프. 호프만-라 로슈 아게 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
WO2010151601A1 (en) * 2009-06-24 2010-12-29 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
JP2013509442A (ja) * 2009-10-29 2013-03-14 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節因子としての二環式ピリジンおよび類似体
EP2558474B1 (en) * 2010-04-13 2015-11-25 Rigel Pharmaceuticals, Inc. 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
CN105859735B (zh) * 2010-12-16 2018-03-09 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法

Also Published As

Publication number Publication date
CA2879497A1 (en) 2014-03-06
BR112015002493A8 (pt) 2019-07-30
RU2612251C2 (ru) 2017-03-03
EP2890698B1 (en) 2017-03-01
CA2879497C (en) 2017-08-01
CN104583215B (zh) 2016-12-07
EP2890698A1 (en) 2015-07-08
CN104583215A (zh) 2015-04-29
WO2014033196A1 (en) 2014-03-06
JP6022691B2 (ja) 2016-11-09
HK1209740A1 (en) 2016-04-08
JP2015526492A (ja) 2015-09-10
KR101697444B1 (ko) 2017-01-17
RU2015108410A (ru) 2016-10-20
BR112015002493A2 (pt) 2017-07-04
US20140065136A1 (en) 2014-03-06
US9346817B2 (en) 2016-05-24
MX2015002501A (es) 2015-06-10
KR20150038466A (ko) 2015-04-08

Similar Documents

Publication Publication Date Title
ECSP13012692A (es) Compuestos tricíclicos inhibidores de la pi3k y métodos de uso
MX361157B (es) Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso.
EA201490859A1 (ru) Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX355852B (es) Compuestos de pirazolo [3,4-c] piridina y métodos de uso.
MX2016007171A (es) Compuestos de heteroaril piridona y azapiridona con funcionalidad electrofila.
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
MX2014005285A (es) Compuestos biciclicos de piperazina.
CO6630133A2 (es) Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
MY191936A (en) Serine/threonine kinase inhibitors
MX2014010589A (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
CR11690A (es) Pirazolo (3,4-b) piridinas como inhibidores de raf
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
MX357502B (es) Derivados de pirrolotriazinona.
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
MX345127B (es) Derivados de tiazol.
AU2013218357A8 (en) Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors

Legal Events

Date Code Title Description
FG Grant or registration